Updated Phase 1 data for ELVN-001 expected mid-2025 as positive enrollment momentum continues Expected monotherapy and combination data from the ELVN-002 Phase 1 trials ...
Takeda is sharpening its oncology focus amid an R&D revamp. Sun Pharma will acquire Checkpoint Therapeutics and an ...
Investment analysts at HC Wainwright upped their Q1 2025 earnings per share estimates for Zymeworks in a note issued to investors on Monday, March 10th. HC Wainwright analyst R. Burns now anticipates ...